Other molecular alterations can also occur in gliomas such as EGFR amplification, p16/14 deletion, Notch overexpression, NF-1/PTEN co-deletion or other mutations e.g. EGFR, PDGFRA, PI3KCA, PTEN, CDKN2A/B and p53 [1, 2]. This evidence concerns the gene CDKN2A and central nervous system cancer.